The anti-virulence activity of the non-mevalonate pathway inhibitor FR900098 towards Burkholderia cenocepacia is maintained during experimental evolution.
Sign Up to like & getrecommendations! Published in 2022 at "Microbiology"
DOI: 10.1099/mic.0.001170
Abstract: Burkholderia cenocepacia infections are difficult to treat and there is an urgent need for alternative (combination) treatments. The use of anti-virulence therapies in combination with antibiotics is a possible strategy to increase the antimicrobial susceptibility… read more here.
Keywords: burkholderia cenocepacia; fr900098; activity; anti virulence ... See more keywords